Literature DB >> 8710879

Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.

M V Blagosklonny1, J Toretsky, S Bohen, L Neckers.   

Abstract

The p53 mutant, 143ala, was translated in vitro in either rabbit reticulocyte lysate (RRL) or wheat germ extract (WGE). In RRL, p53-143ala protein of both mutant and wild-type conformation, as detected immunologically with conformation-specific antibodies, was translated. The chaperone protein HSP90, present in RRL, was found to coprecipitate only with the mutated conformation of p53. Geldanamycin, shown previously to bind to HSP90 and destabilize its association with other proteins, decreased the amount of immunologically detectable mutated p53 and increased the amount of detectable wild-type protein, without affecting the total translation of p53. When translated in WGE, known to contain functionally deficient HSP90, p53-143ala produced p53 protein, which was not recognized by a mutated conformation-specific antibody. In contrast, the synthesis of conformationally detectable wild-type p53 in this system was not compromised. Reconstitution of HSP90 function in WGE permitted synthesis of conformationally detectable mutated p53, and this was abrogated by geldanamycin. Finally, when p53-143ala was stably tansfected into yeast engineered to be defective for HSP90 function, conformational recognition of mutated p53 was impaired. When stable transfectants of p53-143ala were prepared in yeast expressing wild-type HSP90, conformational recognition of mutated p53 was antagonized by macbecin I, a geldanamycin analog also known to bind HSP90. Taken together, these data demonstrate a role for HSP90 in the achievement and/or stabilization of the mutated conformation of p53-143ala. Furthermore, we show that the mutated conformation of p53 can be pharmacologically antagonized by drugs targeting HSP90.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8710879      PMCID: PMC38679          DOI: 10.1073/pnas.93.16.8379

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Structural and functional aspects of basic helix-loop-helix protein folding by heat-shock protein 90.

Authors:  G Shue; D S Kohtz
Journal:  J Biol Chem       Date:  1994-01-28       Impact factor: 5.157

2.  A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40.

Authors:  J Milner; A Cook; M Sheldon
Journal:  Oncogene       Date:  1987       Impact factor: 9.867

3.  Characterization of mutant p53-hsp72/73 protein-protein complexes by transient expression in monkey COS cells.

Authors:  H W Stürzbecher; C Addison; J R Jenkins
Journal:  Mol Cell Biol       Date:  1988-09       Impact factor: 4.272

4.  Sequence-specific transcriptional activation is essential for growth suppression by p53.

Authors:  J A Pietenpol; T Tokino; S Thiagalingam; W S el-Deiry; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

5.  Specific interaction between the p53 cellular tumour antigen and major heat shock proteins.

Authors:  O Pinhasi-Kimhi; D Michalovitz; A Ben-Zeev; M Oren
Journal:  Nature       Date:  1986 Mar 13-19       Impact factor: 49.962

6.  Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.

Authors:  L Whitesell; E G Mimnaugh; B De Costa; C E Myers; L M Neckers
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

7.  Alteration of p53 conformation and induction of apoptosis in a murine erythroleukemia cell line by dimethylsulfoxide.

Authors:  J J Ryan; M F Clarke
Journal:  Leuk Res       Date:  1994-08       Impact factor: 3.156

Review 8.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

9.  Isolation of Hsp90 mutants by screening for decreased steroid receptor function.

Authors:  S P Bohen; K R Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

10.  A temperature-sensitive mutant of human p53.

Authors:  W Zhang; X Y Guo; G Y Hu; W B Liu; J W Shay; A B Deisseroth
Journal:  EMBO J       Date:  1994-06-01       Impact factor: 11.598

View more
  96 in total

Review 1.  Heat shock factor function and regulation in response to cellular stress, growth, and differentiation signals.

Authors:  K A Morano; D J Thiele
Journal:  Gene Expr       Date:  1999

2.  Quantitative assessment of complex formation of nuclear-receptor accessory proteins.

Authors:  K Graumann; A Jungbauer
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

Review 3.  Hsp70 interactions with the p53 tumour suppressor protein.

Authors:  M Zylicz; F W King; A Wawrzynow
Journal:  EMBO J       Date:  2001-09-03       Impact factor: 11.598

Review 4.  Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.

Authors:  H J Ochel; K Eichhorn; G Gademann
Journal:  Cell Stress Chaperones       Date:  2001-04       Impact factor: 3.667

5.  CRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90.

Authors:  Stefan Rudiger; Stefan M V Freund; Dmitry B Veprintsev; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-05       Impact factor: 11.205

6.  17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.

Authors:  Jennifer M Napper; Vincent E Sollars
Journal:  Leuk Res       Date:  2010-06-19       Impact factor: 3.156

7.  V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.

Authors:  O M Grbovic; A D Basso; A Sawai; Q Ye; P Friedlander; D Solit; N Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-21       Impact factor: 11.205

8.  HSP90 protects apoptotic cleavage of vimentin in geldanamycin-induced apoptosis.

Authors:  Mei-Hua Zhang; Jae-Seon Lee; Hee-Jung Kim; Dong-Il Jin; Jong-Il Kim; Kong-Joo Lee; Jeong-Sun Seo
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

9.  Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.

Authors:  Srikanth R Ambati; Eloisi Caldas Lopes; Kohji Kosugi; Ullas Mony; Ahmet Zehir; Smit K Shah; Tony Taldone; Andre L Moreira; Paul A Meyers; Gabriela Chiosis; Malcolm A S Moore
Journal:  Mol Oncol       Date:  2013-12-15       Impact factor: 6.603

10.  Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab.

Authors:  Gang Niu; Zibo Li; Qizhen Cao; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-14       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.